Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | SSTR3 | P32745 | 9/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29933088 | 0.84 | RAB9A (0.64) | NPC1RAB9ASSTR3HDAC4HDAC6 | |
| SCHEMBL14117665 | 0.84 | HDAC4 (0.52) | NPC1RAB9ASSTR3HDAC4HDAC6 | |
| SCHEMBL31359373 | 0.84 | F10 (0.56) | HDAC4HDAC6CNR1TAS1R3TAS1R1 | |
| SCHEMBL7348185 | 0.83 | NPSR1 (0.58) | NPC1RAB9ASSTR3HDAC4HDAC6 | |
| SCHEMBL13495007 | 0.83 | NPSR1 (0.58) | NPC1RAB9ASSTR3HDAC4HDAC6 | |
| SCHEMBL7348191 | 0.83 | NPSR1 (0.58) | NPC1RAB9ASSTR3HDAC4HDAC6 | |
| SCHEMBL8740548 | 0.83 | NPSR1 (0.58) | NPC1RAB9ASSTR3HDAC4HDAC6 | |
| SCHEMBL7348189 | 0.83 | NPSR1 (0.58) | NPC1RAB9ASSTR3HDAC4HDAC6 | |
| SCHEMBL8740547 | 0.83 | NPSR1 (0.58) | NPC1RAB9ASSTR3HDAC4HDAC6 | |
| SCHEMBL28310450 | 0.83 | NPC1 (0.62) | NPC1RAB9ASSTR3HDAC4TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | NIPPON SHINYAKU CO., LTD. (JP) | 2025-12-30 | — | — | US | disclosed |
| US-20230101484-A1 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | NIPPON SHINYAKU CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| CN-115315421-A | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2022-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | PDGFRA, PDGFRB, PDGFA | NPC1 4118/4885RAB9A 2815/4885SSTR3 1326/4885 |
| US-20230101484-A1 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | PDGFRB, PDGFRA, PDGFA | NPC1 4509/4885RAB9A 2531/4885SSTR3 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.